講座案内 >
講座の概要
がんは我が国の死亡原因の第1 位を占めている。このような状
況下において,不十分ではあるが,がん医療は着実な進歩を遂げ
てきた。特に最近はがんの分子生物学的研究の成果により,治療
法は大きく変貌しつつある。腫瘍内科学講座では,消化器がん(食
道がん,胃がん,大腸がん,肝臓がん,胆管がん,膵臓がんなど),
呼吸器がん(肺がんなど),原発不明がんに対する診断と薬物療法
を中心としたがん診療の実践,研究,教育を行っている。以下は
腫瘍内科学教育の指導内容と主な研究内容である。専門医育成のための指導内容
-
1)薬物療法(抗がん剤,分子標的薬剤・ホルモン治療・抗体治療を含む)の適応
2)治療選択法の習得
3)支持療法の習得
4)抗がん剤に関する薬理の理解
5)がん臨床研究の方法論の理解と実際
6)基礎的研究の計画,実施
-
1)進行肺がん,消化器がんに対する効果的化学療法の開発
2)肺がん,消化器がん術後補助化学療法の開発
3)新規抗がん剤の臨床開発
4)新規分子標的薬剤の臨床開発
5) 新しい抗がん剤の感受性に関わる遺伝子異常の同定(個別化医療)
6)抗がん剤に関する薬理ゲノム学的研究
Outline of Department
Cancer has been the leading cause of death in Japan. Although
more must be done, cancer care has been making
steady progress. In particular, recent breakthroughs in molecular
biological research on cancer have led to major
changes in treatment methods. The Medical Oncology
Course offers opportunities for practice, research, and education
concerning diagnosis and treatment, particularly
drug therapy, of cancers of the digestive tract (esophageal
cancer, gastric cancer, colon cancer, liver cancer, bile duct
cancer, pancreatic cancer), respiratory tract (e.g. lung cancer),
and unknown origin. The teaching contents and primary
areas of research in the Medical Oncology Course
are listed below.Teaching contents for nurturing specialists
-
1) Indications for drug therapy (anticancer agents, including
molecular-targeted agents, hormone treatment, and antibody
treatment)
2) Methods for selecting treatment
3) Supportive therapy
4) Pharmacology of anticancer agents
5) Methodology and implementation of clinical cancer research
6) Planning and implementation of basic research
Primary areas of research
-
1) Development of effective chemotherapy for advanced
lung cancer and gastrointestinal cancer
2) Development of adjuvant chemotherapy for lung cancer and gastrointestinal cancer
3) Clinical development of new anticancer agents
4) Clinical development of new molecular-targeted agents
5) Identification of gene abnormalities related to sensitivity to new anticancer agents (individualized medicine)
6) Pharmacogenomics research on anticancer agents